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Abstract
Background: HIV-1 Tat protein is known to be associated with neuroinflammation, a condition that develops in
almost half of patients infected with HIV-1. HIV-1 Tat can alter glial neuroprotective functions, leading to
neurotoxicity within the CNS. HIV-1 Tat is known to be secreted from productively infected cells and can affect
neighboring uninfected cells by modulating cellular gene expression in a bystander fashion.
Methods: We were interested to study whether exogenous exposure to HIV-1 Tat-C protein perturbs the microRNA
(miRNA) expression profile of human microglial cells, leading to altered protein expression. We used protein
expression and purification, miRNA overexpression, miRNA knockdown, transfection, site-directed mutagenesis,
real-time PCR, luciferase assay and western blotting techniques to perform our study.
Results: HIV-1 Tat-C treatment of human microglial cells resulted in a dose-dependent increase in miR-32
expression. We found that tumor necrosis factor-receptor–associated factor 3 TRAF3) is a direct target for miR-32,
and overexpression of miR-32 in CHME3 cells decreased TRAF3 both at the mRNA and the protein level. Recovery
of TRAF3 protein expression after transfection of anti-miR-32 and the results of the luciferase reporter assay
provided direct evidence of TRAF3 regulation by miR-32. We found that the regulation of interferon regulatory
factor 3 (IRF3) and IRF7 is controlled by cellular levels of TRAF3 protein in microglial cells, as after overexpression of
miR-32 and application of anti-miR-32, expression levels of IRF3 and IRF7 were inversely regulated by expression
levels of TRAF3. Thus, our results suggest a novel miRNA mediated mechanism for regulation of TRAF3 in human
microglial cells exposed to HIV-1 Tat C protein. These results may help to elucidate the detrimental
neuroinflammatory consequences of HIV-1 Tat C protein in bystander fashion.
Conclusion: HIV-1 Tat protein can modulate TRAF3 expression through miRNA mediated pathway and can change
the downstream expression of IRF3 and IRF7. This study demonstrates a novel mechanism of HIV-1 Tat C
protein-mediated perturbation of miRNA, resulting in dysregulation of cellular TRAF3.
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Background
AIDS (acquired immunodeficiency syndrome) is caused
by human immunodeficiency virus (HIV), which results
in compromised immunity in the host. Although sys-
temic immune cells such as CD4 positive T cells and
macrophages are the prime targets for HIV infection,
other cells, such as microglia and astrocytes, the resident
cells of the CNS, are also reported to be productively
infected by HIV [1]. Neuroinflammatory consequences
of HIV infection into the CNS lead to complex neuro-
psychological and behavioral changes, collectively known
as HIV-associated neurological disorder (HAND) [2].
Recent reports show that the prevalence of neurocogni-
tive disorders has risen from 30% to 50% of patients
infected with HIV [3]. HIV entry into the CNS is
reported to take place during early acute infection [4]
via infected macrophages, which cross the blood–brain
barrier and transport the virus inside the CNS [5].
Antibodies against the HIV-1 transactivator of transcrip-
tion (Tat) protein have been reported in the brains of
patients with HIV encephalitis [6]. The HIV-1 Tat protein
is essential for transactivation of viral and cellular genes [7],
and has been reported to have a role in neuroinflammation,
which ultimately leads to HIV-associated neurocognitive
disorders [8].
HIV Tat has been shown to be the first protein expressed
during HIV infection [9], and is capable of being actively
released from the infected cells. Released Tat protein can
be taken up by nearby infected and uninfected cells, thus
affecting them in a bystander fashion [9]. In the CNS,
microglia and astrocytes are often the first cells to respond
to viral infection [10]. Microglia are resident macrophages
of the CNS, and comprise about 10% of the total cell popu-
lation of the brain [11]. Microglia protect the brain from
pathogens, but overactivation of microglia can also result
in inflammation, with subsequent damage to the neurons
and hampering of brain functions [12,13]. The inflamma-
tory mediators released by microglia strongly influence
neurons and their ability to process information. Exogen-
ous exposure of Tat mimics the extracellular release of
HIV Tat protein from productively infected cells during
HIV infection and acts as a model of the pathophysiological
changes induced by Tat in bystander fashion. Neuropatho-
logical changes in the brains of patients infected with HIV
have been attributed to various factors, including HIV Tat
protein, but the exact mechanism of HIV Tat-mediated
neuroinflammation is not well understood [14].
MicroRNAs (miRNAs) belong to a class of small non-
coding RNAs ranging from 19 to 21 nucleotides in
length, which are capable of regulating almost all cellu-
lar processes by suppressing translation of their target
mRNAs [15,16]. Mature miRNAs are generated from
longer primary RNA transcripts (pri-miRNAs), which
are processed into shorter transcripts by the enzymes
Drosha in the nucleus and Dicer in the cytoplasm [15,17].
Dysregulation of miRNA expression and function has been
shown to be correlated with the altered levels of protein
expression [18]. miRNA-mediated modulation of protein
expression has been reported in various types of cancers
and neurodegenerative diseases [19], and dysregulation of
miRNAs has been reported in various neurological diseases.
The CYP2E1 gene, a cytochrome p450 isoform, is asso-
ciated with Parkinson disease, and is regulated via miR-378
[20].
Changes in miRNA expression patterns have also been
reported in HIV infection [19]. The HIV Tat protein has
been reported to modulate neuronal functions via pertur-
bations in the miRNA expression. Tat-mediated induction
of miR-34a has been shown to downregulate specific
genes [21], and this in turn leads to physiological changes
in neurons, resulting in neuronal deregulation, neuronal
loss, and consequently the development of HAND.
In this study, we examined whether HIV Tat protein
can affect the levels of cellular proteins in uninfected cells
in a bystander fashion by modulating miRNA expression
patterns.
Tumor necrosis factor (TNF) receptor-associated factors
(TRAFs) are intracellular adaptor proteins that bind to the
cytoplasmic domain of TNF receptors and mediate down-
stream signaling [22]. The TRAF family is comprised of six
proteins having a regulatory role in immune signaling.
TRAF2 and TRAF5 have been reported to have positive
functions, and TRAF3 and TRAF6 have both positive and
negative regulatory functions in activation of the canonical
nuclear factor kappa B (NF-κB) pathway [23,24]. TRAF3 is
a major regulator of type I interferon (IFN) production and
the innate antiviral response [25]. TRAF3 regulates both
innate and adaptive immunity by modulating signaling
mediated by various receptors such as Toll-like receptors,
TNF receptors, and lymphotoxin-β receptor (LTBR) [12],
and deficiency of TRAF3 has also been implicated in pri-
mary immunodeficiency diseases [26]. TRAF3 is a molecu-
lar switch that inhibits the LTBR-dependent activation of
NF-κB1 [27], and has been reported to be capable of sup-
pressing canonical NF-κB activation and downstream gene
expression both in vitro and in vivo [28].
Degradative ubiquitination of TRAF3 after viral infec-
tion has been reported to be essential for virus-triggered
interferon regulatory factor (IRF)3 activation and IFN in-
duction [29]. Various studies have shown that inhibition of
TRAF3 results in activation of both the canonical and
non-canonical NF-κB activation pathways [27]. Collect-
ively, these reports suggest that TRAF3 is an important
suppressor of inflammatory responses through negative
regulation of the canonical and noncanonical NF-κB
pathways.
The mechanism of TRAF3 regulation in bystander
cells through extracellularly secreted HIV Tat protein
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has not been reported to date. This study is the first, to our
knowledge, to report that TRAF3 is targeted by miR-32.
HIV-1 Tat C exposure leads to the upregulation of miR-32,
which targets TRAF3 and regulates it post-transcriptionally
. This finding demonstrates how extracellularly secreted
viral proteins might modulate expression of their target




Human microglial cells (CHME3) and HeLa cells were
grown in DMEM (catlogue number 12100-046; Gibco-
BRL, Gaithersburg, MD, USA) supplemented with 10%
fetal bovine serum and 100 U of penicillin and 100 μg/ml
streptomycin (10378016; Gibco-BRL). CEM-GFP cells
(NIH-AIDS Reagent Program, Germantown, MD, USA)
were cultured in RPMI 1640 (23400-021; Gibco-BRL)
supplemented with 10% fetal bovine serum (16000-044;
Gibco BRL), 2 mmol/l glutamine, 100 U/ml penicillin,
and 100 U/ml streptomycin. All cells were incubated at
37°C in a humidified chamber supplemented with 5%
CO2.
Expression and purification of HIV tat protein
The tat-c gene was amplified from HIV-1 infected cells
using the primer set listed in Table 1. The tat-c gene was
cloned into the pET-21b bacterial expression vector. The
His-tag was attached to Tat at the C terminal. To express
recombinant Tat C protein, the Escherichia coli BL21
(DE3) strain was used. Protein production was induced for
3 hours, by adding isopropyl-β-D-thio-galactoside to give a
final concentration of 1 mmol/l. Cell pellets were resus-
pended in 20 ml of lysis buffer (50 mmol/l phosphate buffer
pH 7.9, 300 mmol/l KCl, 0.4 mmol/l EDTA, 10 mmol/l
imidazole, 0.2 mmol/l phenylmethanesulfonyl fluoride,
1 mmol/l dithiothreitol, 10% glycerol, and 0.1% Triton-X
100). Cells were lysed by sonication, and proteins were
purified by affinity chromatography using nickel-
nitrilotriacetic acid (Ni-NTA) columns. Finally, Tat protein
was eluted with phosphate buffer (pH 8.0) and 300 mmol/l
imidazole, and was further purified and concentrated by
centrifugal concentrators (Amicon MWCO 3 kDa; Milli-
pore Corp., Billerica, MA, USA) and centrifugation was
done at 4000 rpm, then resuspended in 30 mmol/l phos-
phate buffer, 70 mmol/l KCl, and 1 mmol/l DTT, and
stored at −70°C. The identity of the recombinant Tat
proteins was confirmed by western blot analysis using anti-
Tat antibody (4138; NIH AIDS Research and Reference
Reagent Program), and the level of endotoxin in recom-
binant Tat-C protein was checked by LAL assay (Lonza
50–647 U) in accordance with the manufacturer’s
instructions.
Transactivation assay of HIV Tat protein
To test the functionality of the HIV Tat protein, we per-
formed a transactivation assay using CEM-GFP cells (3655;
NIH AIDS Research and Reference Reagent Program) con-
taining a stably integrated green fluorescent protein (GFP)
gene under the control of the HIV subtype B long terminal
repeat (LTR). Cells were transfected with 5 μg/ml of puri-
fied Tat-C protein with a commercial transfection reagent
(71281–3; ProteoJuice; Novagen/Millipore Corp., Billerica,
MA, USA). GFP expression was visualized by fluorescence
microscopy (Axio Imager; Carl Zeiss, Jena, Germany).
Immunostaining and nuclear localization of HIV-1 Tat C
protein
To track the localization of HIV-1 Tat C protein, CHME3
cells were seeded onto sterilized coverslips in six-well cul-
ture plates. After cells had achieved confluency, they were
treated with 5 μg/ml Tat C protein. After 12 hours of
treatment, cells were washed with PBS and fixed in 4%
paraformaldehyde. Cells were permeabilized with 0.25%
Triton X-100, and blocked with 3% BSA for 30 minutes,
then incubated with the monoclonal Tat antibody (1:1000)
overnight. Cells were washed with PBS and incubated with
the secondary antibody conjugated to Alexa 488 (A-11008;
Invitrogen Corp., Carlsbad, CA, USA). Cells were visualized
under a fluorescence microscope (Axio Imager; Carl Zeiss,
Jena, Germany).
MicroRNA targets predictions
Bioinformatic prediction tools PicTar (http://pictar.mdc-
berlin.de), Target Scan (version 5.2; http://www.targetscan.
org) were used to identify the potential targets of miR-32.
The miR-32 target binding sites in the 3′ untranslated
Table 1 List of primers
Gene Direction Primer sequence 5′!3′












MUT TRAF3 3′ UTR Forward CAACAAGATAAATGCTGTCAGAGAAGG3′
Reverse CCTTCTCTGACAGCATTTATCTTGTTG 3′
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region (UTR) of human TRAF3 transcripts were identified
with TargetScan Human software as above.
Tat treatment on human microglial cells
The human microglial cell line (CHME3) was grown
till 75% confluency, and exposed to HIV Tat protein
at 500 ng/ml concentration in serum-free media.
After 24 hours of treatment, CHME3 cells were har-
vested for RNA isolation and protein studies.
RNA isolation and microRNA assay
RNA isolation was performed with a commercial kit
(217004; miRNeasy Mini Kit; Qiagen Inc., Valencia, CA,
USA). The cDNA synthesis for miRNA was performed
using miRNA specific primers and a commercial kit
(4366596; TaqMan Reverse Transcription Kit; Applied
Biosystems, Foster City, CA, USA), with the following
settings: 16°C for 30 minutes, 42°C for 30 minutes, and
85°C for 5 minutes. miRNA assays were performed using
quantitative (q)PCR with miRNA-specific Taqman
probes and a master mix (4324018; Universal PCR Mas-
ter Mix Applied Biosystems), using settings of 95°C for
10 minutes, followed by 40 cycles of 95°C for 15 seconds
and 60°C for 60 seconds in a thermal cycler (ABI 7900;
Applied Biosystems).
Cell lysates and western blot analysis
RIPA buffer (150 mmol/l NaCl, 50 mmol/l Tris. HCL
pH 7.0, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS,
and 1X protease inhibitor cocktail) was used to lyse
cells. Protein concentrations were determined by the
Bradford assay (500-0006; Bio-Rad Laboratories, Inc.,
Hercules, CA, USA). Equal amount of proteins were
separated in a 12% polyacrylamide gel, and transferred
onto polyvinylidene fluoride membrane at 100 V for 2
hours. The membrane was blocked in 5% skimmed milk
powder prepared in Tris-buffered saline with Triton X-
100 (TBS-T). Membranes were incubated overnight at 4°
C with primary antibody (1:1000). After three washes of
10 minutes each with TBST, the horse-radish
peroxidase-conjugated secondary antibody was applied
for 45 minutes. Membranes were again washed in TBS-
T three times and developed (34095; Super Signal Devel-
oping Reagent; Pierce Biotechnology Inc., Rockford, Illi-
nois, USA).
MicroRNA overexpression
Cells were seeded into six-well plates at 60% confluency
1 day before transfection. Transfection mixtures were pre-
pared in commercial medium (11058–021; Opti-MEM;
Invitrogen Corp.), and cells were kept in antibiotic-free
medium during transfection. miR-32 overexpression was
performed by transfecting the miRNA expression plasmid
(SC400329; Origene Technologies, Rockville, MD, USA)
using transfection reagent (11668–019; Lipofectamine
2000; Invitrogen Corp.). The empty vector was used as
vehicle control. miR-32 overexpression was confirmed by
qPCR using TaqMan probes specific to miR-32.
Reverse transcription and real-time PCR
RNA was subjected to DNAse treatment (M0303L; New
England Biolabs, Beverly, MA, USA) for 30 minutes at
37°C. cDNA synthesis was performed with reverse tran-
scriptase (11904–18; Superscript II; Invitrogen) in accord-
ance with the manufacturer’s protocol. PCR conditions
were: 65°C for 5 minutes, 25°C for 10 minute, 42°C for 50
minutes, and 70°C for 10 minutes, and finally RNAse H
treatment for 20 minutes at 37°C. SYBR Green (4309155;
Applied Biosystems) was used for qPCR. The primer
sequences used in the study for qPCR are listed in Table 1.
Transfection with anti-microRNA (microRNA inhibitor)
CHME3 cells were transfected (Lipofectamine 2000; Invi-
trogen Corp.) with 100 pmol of anti-miR-32 (AM12584;
Ambion, Foster City, CA, USA) and Cy3-labeled control
anti-miR (AM17011; Ambion). After 48 hours of transfec-
tion, cells were pelleted for RNA isolation and protein lys-
ate preparation. Transfection efficiency was assessed by
visualizing the fluorescence of Cy3-labeled control anti-
miR. Knockdown of miR-32 in anti-miR transfected cells
was assessed using an miR-32 assay. TRAF3 protein ex-
pression in cells transfected with anti-miR-32 was ana-
lyzed using western blotting with anti-TRAF3 antibody
(ab76147; Abcam, Cambridge, MA, USA).
Luciferase reporter assay
HeLa cells were seeded in six-well plates and co-
transfected (Lipofectamine 2000; Invitrogen Corp.)
with luciferase reporter clones of TRAF3 3′ UTR and a
miR-32-expressing plasmid. The TRAF3 3′ UTR con-
struct in pMirTarget (SC206836; Origene Technolo-
gies) and miR-32 construct as pCMV-Mir (SC400329;
Origene Technologies) were used. A mutation in the
3′ UTR of TRAF3 in miR-32 binding sites was created
by deleting the TATT sequence at position 463 to 466
of the 3′ UTR using the primer set listed in Table 1. A
site-directed mutagenesis kit (200518; Stratagene, La
Jolla, CA, USA) was used for generating the deletion
mutations. Both the wild-type (WT) and mutant 3′
UTR of TRAF3 were transfected along with miR-32 ex-
pression clones in HeLa cells. Cells were harvested
after 24 hours of transfection for luciferase assays
(E4030; Luciferase Assay Kit; Promega Corp., Madison,
WI, USA) in accordance with the manufacturer’s proto-
col. A β-galactosidase assay (E2000; Promega Corp.)
was used for normalization.
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Statistical analysis
Results are shown as the mean and standard error of the
mean from three independent repeated experiments.
Results are shown relative to controls in miR-32 assay.
The level of significance (P values) between treated and
untreated (control) groups was analyzed using the Stu-
dent’s t-test, and P< 0.05 was considered significant.
Results
Expression and purification of tat protein
We could express the recombinant HIV-1 Tat C protein
successfully by using the standard procedures as described
in material and methods section. After the purification of
HIV-1 Tat C protein; we used LAL assay to determine the
endotoxin levels in the purified protein. The concentra-
tion of endotoxin was found to be 0.04 EU/μg of protein,
which is greatly below the acceptable limits. To confirm
the biological activity of the recombinant Tat protein, the
transactivation assay was performed in CEM-GFP cells
with stably integrated HIV-1 LTR. These cells showed
enhanced transcription after 24 hours of Tat C transfec-
tion, as visualized by GFP expression (data not shown).
Purified Tat C protein was found to be transcriptionally
active as it significantly enhanced GFP expression through
the transcription of HIV LTR.
HIV-1 Tat C upregulates the expression level of microRNA
32
HIV-1 Tat protein is known to activate the cellular genes,
including expression of small RNAs [30]. CHME3 cells
were treated with increasing dose of Tat-C protein to
study the dose-dependent effect of Tat protein on miR-32
expression levels. Expression levels of miR-32 were
assessed by qPCR using miR-32 specific TaqMan probes.
A gradual increase in miR-32 expression levels was seen
after Tat C treatment in a dose-dependent manner, with a
2.2-fold change in miR-32 expression seen in cells treated
with 100 ng/ml of Tat C protein, and a 4.4-fold increase in
cells treated 2.5 μg/ml of Tat C (Figure 1a).
HIV-1 Tat C decreases tumor necrosis factor
receptor-associated factor 3 levels in CHME3 cells
Using bioinformatic prediction tools (Pictar, TargetScan),
we found that TRAF3 is a putative target of miR-32. To in-
vestigate whether changes in miR-32 expression affect the
levels of TRAF3 (Figure 1A), we assessed the expression
level of cellular TRAF3 protein in HIV-1 Tat C-treated
CHME3 cells. TRAF3 protein level decreased sharply with
the increase in Tat-C mediated upregulation of miR-32
(Figure 1b), suggesting that TRAF3 can be a direct target of
miR-32 and that its expression can be modulated by
changes in miR-32 expression.
Figure 1 Expression of miR-32 increases with Tat C treatment in a dose-dependent manner. (a) CHME3 cells were treated with an
increasing dose of HIV-1 Tat C protein. After 24 hours, cells were harvested for RNA isolation and protein lysate preparation. miR-32 assays were
performed by quantitative PCR with TaqMan probes and primers specific for human miR-32. Data was normalized to the expression level of the
small RNA, RNU24, and results are shown as fold change compared with untreated control. Changes in miR-32 expression level were significant
(P≤ 0.05). (b), Western blot analysis for tumor necrosis factor receptor-associated factor 3(TRAF3) of the same samples treated with increasing
concentrations of Tat C, showing a gradual reduction in TRAF3 protein expression. (c) Western blot image intensity was normalized to β-tubulin.
All experiments were performed three times and are presented as mean± SE. Changes in the level of expression of TRAF3 in response to
increasing dose of Tat C were significant (**P≤ 0.005, *P≤ 0.05) compared with the untreated group.
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Figure 2 HIV-1 Tat C protein downregulates tumor necrosis factor receptor-associated factor 3 (TRAF3) protein expression. (a) Western
blot analysis of TRAF3 in CHME3 cells exposed to HIV-1 Tat C protein. Treating CHME3 cells with 500 ng/ml Tat C significantly reduced the cellular
TRAF3 protein level. (b) Densitometry analysis of TRAF3, normalized to β-tubulin image density. The change in TRAF3 expression level in the
treated group versus the untreated control group was significant (*P≤ 0.05). (c) Quantitative PCR analysis of TRAF3 in CHME3 cells exposed to HIV
Tat C protein. The graph is representative of three independent experiments. All experiments were performed at least three times and data are
presented as mean± SE. **P≤ 0.005.
Figure 3 HIV-1 Tat protein exerts no significant effect on the RNA interference machinery. (a) Nuclear localization of Tat C protein in
CHME3 cells exposed to recombinant HIV-1 Tat C protein. CHME3 cells were treated with Tat C protein at 5 μg per ml of culture media for 24
hours. Cells were then washed with PBS, fixed and stained with anti-Tat antibody, and visualized with Alexa 488-conjugated fluorescent antibody.
(b) Western blot analysis for Dicer and Drosha in CHME 3 cells exposed to Tat C for 24 hours showed no significant change in the expression of
either protein. β-tubulin was used as loading control for normalizing the image density. (c) Densitometry quantification for Drosha and Dicer
enzyme normalized to β-tubulin. All experiments were performed three times, and data are presented as mean± SE.
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In another experiment, CHME3 cells were exposed to
Tat C (500 ng/ml) for 24 hours, and both mRNA and
protein expression of TRAF3 decreased significantly
(P< 0.05)(Figure 2A,C).
No significant change in drosha and dicer levels after Tat
C treatment
After exposing the CHME3 cells to the HIV-1 Tat C
protein, the cellular localization of HIV-1 Tat C protein
in CHME3 cells was visualized by immunostaining
(Figure 3A). The localization study confirmed that re-
combinant HIV Tat C protein was internalized by cells
and entered the nucleus (Figure 3a).
Viruses or viral proteins are known to influence the
cellular RNA interference machinery. To assess whether
changes in miR-32 expression levels after Tat C treat-
ment involve the miRNA biogenesis machinery, we
assessed the expression of Dicer and Drosha, and found
no significant changes in their expression (Figure 3b), in-
dicating that the Tat protein does not modulate the
miRNA biogenesis machinery in CHME3 cells.
microRNA 32 overexpression downregulates expression
level of cellular tumor necrosis factor receptor-associated
factor 3
A pCMV-miR-32 construct encoding miR-32 was trans-
fected into CHME3 cells, and the expression level of miR-
32 was determined after 24 hours of transfection. The
level of miR-32 was 7.5-fold higher after transfection
(P< 0.05) (Figure 4B). Therefore, we investigated expres-
sion of TRAF3 protein in miR-32-transfected CHME3
cells to establish a correlation between the expression level
of miR-32 and that of TRAF3 protein. We found a reduc-
tion in protein expression and mRNA levels of TRAF3
after Tat C treatment, as well as reduction in the expres-
sion of TRAF3 protein as a consequence of miR-32 over-
expression (Figure 4A). The overexpression of miR-32
(7.5-fold higher) led to a 60% reduction in the TRAF3 ex-
pression level compared with the cells transfected with
empty vector. qPCR analysis confirmed the change in
TRAF3 transcription after miR-32 overexpression in
CHME3 cells (Figure 4D) Thus, miR-32 was found to tar-
get TRAF3, suggesting a direct link between expression of
miR-32 and TRAF3.
Figure 4 Overexpresssion of miR-32 suppresses tumor necrosis factor receptor-associated factor 3(TRAF3) protein expression. (a)
Western blot analysis for TRAF3 in CHME3 cells after miR-32 overexpression. Plasmid pCMV-miR-32 was transfected into CHME3 cells. The empty
vector was used as the negative control. Cell lysates were prepared after 24 hours of transfection, and western blot analysis was performed using
anti-TRAF3 antibody. miR-32 overexpression significantly reduced both mRNA and protein levels of TRAF3 (P≤ 0.05) (indicated by * in the
transfected group) compared with empty vector. (b) Quantitative (q)PCR analysis of miR-32 overexpression in CHME3 cells, using TaqMan miR-32
assay. miR-32 expression was found to be 7.5-fold higher in miR-32-overexpressed cells. (c) Densitometry quantification of TRAF3 normalized to β-
tubulin. (d) qPCR analysis for detection of changes in transcript level of TRAF3 after miR-32 overexpression in CHME3 cells. All experiments were
performed at least three times and data are presented as mean± SE.
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Anti-microRNA 32 rescues the expression level of tumor
necrosis factor receptor-associated factor 3 protein
This experiment was carried out to test the specificity of
miR-32-mediated downregulation of TRAF3. CHME3 cells
were transfected with anti-miR-32 (an miRNA inhibitor)
along with a scrambled Cy3-labeled anti-miR-32 as nega-
tive control. The objective was to block the effects of miR-
32 expression, which would confirm that these effects were
due solely to the presence of miR-32. Anti-miR-32 was
transfected into CHME3 cells, and this was followed by
Tat C treatment. This procedure resulted in enhanced ex-
pression of TRAF3 (Figure 5c) and recovered the cellular
TRAF3 level almost to that of control cells (Figure 5C,D).
This demonstrates that cellular TRAF3 level can be recov-
ered with the help of an antagonist against miR-32.
microRNA 32 directly targets the 3′ untranslated region of
tumor necrosis factor receptor-associated factor 3
To test the mode of interaction between miR-32 and
TRAF3, a luciferase assay was performed. In this experi-
ment, luciferase reporter constructs was co-transfected
with the miR-32 overexpression plasmid. In this reporter
construct, the TRAF3 3′ UTR is flanked upstream by
firefly luciferase coding sequences. Another construct
was generated having deletions in the predicted binding
site in the 3′ UTR of TRAF3 complementary to the seed
region of miR-32. A deletion mutant was generated by
site-directed mutageneis to modify the complementary
sequence in the 3′ UTR of TRAF3 to abrogate the
seven-mer match of the seed region of miR-32 and the
TRAF3 3′ UTR. The empty construct without 3′ UTR
of TRAF3, was simultaneously transfected with miR-32
overexpression plasmids as a negative control. A signifi-
cant reduction of up to 80% in the luciferase activity was
seen when the TRAF3 3′ UTR was cotransfected with
miR-32 (P ≤ 0.0005). The TRAF3 3′ UTR mutant did not
show a significant reduction in luciferase activity when
transfected with miR-32. The TRAF3 3′UTR was trans-
fected with a irrelevant miR-146 expression construct,
which showed a much lower non-specific decrease in
the luciferase activity (Figure 6b). The luciferase expres-
sion level of the control cells (transfected with TRAF3
3′UTR) was considered as 100%, and the reduction by
miRNAs has been shown relative to this.
Figure 5 Anti-miR-32 transfection rescues tumor necrosis factor receptor-associated factor 3 (TRAF3) protein expression in CHME3
cells. (a) Transfection efficiency of anti-miR, by using Cy3-labeled anti-miR as negative control. (b) Quantitative (q)PCR analysis of cellular miR-32
level after anti-miR-32 transfection, to confirm the suppression of miR-32. The expression level of miR-32 decreased by 40% in cells transfected
with anti-miR-32; compared to cells transfected with scrambled anti-miR negative control (*P≤ 0.05). (c) Western blot analysis of TRAF3 in CHME3
cells after anti-miR-32 transfection, showing the recovery of TRAF3 expression level in cells treated with anti-miR-32 and anti-miR-32 plus Tat.
Anti-miR-32 transfection was performed at a concentration of 100 pmol/l. After 24 hours of anti-miR-32 transfection, a set of transfected cells
were treated with 500 ng/ml Tat C protein to augment the cellular expression level of miR-32. (d) Densitometry analysis of TRAF3 normalized to
β-tubulin. There was a significant (**P≤ 0.005) recovery of TRAF3 expression level.
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Interferon regulatory factor (IRF)3 and IRF7 are perturbed
by tat C treatment and microRNA 32 overexpression
IRF3 and IRF7 are constitutively located in the cytoplasm,
and are phosphorylated and translocated to the nucleus in
response to a stimulatory trigger. After translocation to the
nucleus, they induce the expression of IFNs and other in-
flammatory cytokines. TRAF3 is regarded as a dual-mode
repressor of the NF-κB pathway, having an important role
in regulating the IFN response of cells during infections.
Tat C treatment and miR-32 overexpression resulted in the
same trend of activation of IRF3 and IRF7 (Figure 7).
Western blot analysis showed higher levels of phosphory-
lated IRF3 and IRF7 in Tat C-treated cells (Figure 7A,B)
and a similar trend was seen in cells overexpressing miR-
32. Total protein levels of IRF3 and IRF7 were also found
to be higher in Tat C treated and miR-32 overexpressing
CHME3 cells (Figure 7). Downregulation of TRAF3 after
Tat C treatment and miR-32 overexpression, and increased
levels of phosphorylation of IRF3/7 suggest a negative
regulatory role of TRAF3 in controlling IRF3 and IRF7 ex-
pression, which is in accordance with previously shown
function of TRAF3 [27].
The expression levels of total IRF3, IRF7 and pIRF3/7
in CHME3 cells transfected with anti-miR-32 were ana-
lyzed by western blotting. Expression levels of total IRF3
and IRF7 decreased (Figure 8A,B) in cells transfected
with anti-miR-32, but phosphorylation of IRF3 and IRF7
increased compared with the scrambled anti-miR trans-
fection (negative control).
Both;the Tat C treatment and miR-32 overexpression
increases the IRF3 and IRF7 expression at the transcript
level (Figure 9A,B). The suppression of cellular miR-32 by
using anti-miR-32, resulted in the reduced expression of
both IRF3 and IRF7 at the transcript level (Figure 9C).
Discussion
Microglia are brain resident macrophages that are
involved in crucial regulatory processes of development
and surveillance of the neural environment during in-
jury, infection, and repair [11]. As the primary source
for pro-inflammatory cytokines, microglial cells are
implicated as pivotal mediators of neuroinflammation.
Activated microglia leading to an inflammatory re-
sponse has been reported in many models of neuroin-
flammation and neurotoxicity [11]. Viruses attempt to
modulate the cellular environment using various strat-
egies, changing the expression pattern of protein-coding
genes and non-coding genes such as miRNAs [31].
Small RNAs have been reported to play an important
role in neuroviral infections [21]. In the present study,
we identified a novel mechanism by which HIV-1 Tat C
protein can change the expression of specific genes in
Figure 6 miR-32 directly targets the 3′-UTR of tumor necrosis factor receptor-associated factor 3 (TRAF3). (a) Seed sequence in miR-32
and complementary sequence in the 3′ UTR of TRAF3 mRNA showing seven-mer binding in wild-type (WT) TRAF3 3′ UTR. A deletion mutation of
4 base pairs in the 3′ UTR of TRAF3 was generated by site-directed mutagenesis. This alteration in the 3′ UTR sequence of TRAF3 abrogated the
interaction of miR-32 and the 3′ UTR of TRAF3, resulting in translational derepression. (b) Luciferase assays were performed by transfecting HeLa
cells with pCMV-β-gal (normalization control), WT TRAF3 3′ UTR and mutated (MUT) TRAF3 3′ UTR plasmids, along with pCMV-miR-32 plasmids.
Normalized luciferase light units of control cells are presented as 100 units, and relative light units (RLU) of other treatments are shown
accordingly. All experiments were performed three times and data are presented as mean± SE (error bars). ***P ≤0.0005.
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microglial cells by modulating expression of specific
miRNAs. Minor variations in miRs can result in changes
in the fine-tuning of cellular and biological processes
[32,33]. Previous studies have shown that Tat induces
molecular processes such as the proteasome-ubiquitin
pathway for degradation and consequent downregula-
tion of target protein [34]. In this study, we have for the
first time identified a novel pathway by which HIV-1 Tat
C protein can interfere with expression of the TRAF 3
gene in microglial cells by altering miRNA expression.
It has been shown that HIV Tat protein can be taken
up by cells through the cellular endocytic machinery
[35,36]. The immunostaining of recombinant HIV-1 Tat
C-treated cells showed that HIV-1 Tat C protein moves
to the nucleus and remains there to execute its transacti-
vational functions. We also investigated the effect of
HIV-1 Tat C protein on the miRNA biogenesis machin-
ery because biogenesis of miRNAs begins in the nucleus.
To study the effect on miRNA biogenesis, we examined
the effect of HIV-1 Tat C protein on the major enzymes
Drosha and Dicer, which play key roles in miRNA bio-
genesis, but we did not find any significant change in
their expression.
Exposure of CHME3 cells to HIV-1 Tat C protein
increased the expression level of cellular miR-32, accom-
panied by depletion of TRAF3 at protein level. The re-
ciprocal relationship between increased miR-32 levels
and reduced TRAF3 expression during Tat C exposure
on CHME3 cells suggested an interaction between miR-
32 and TRAF3. HIV Tat protein has been reported to in-
duce the expression level of miR-128 in primary cortical
neurons, which targets the 3′ UTR of the presynaptic
protein SNAP25. This targeting leads to the suppression
of SNAP25, whereas an anti-miR-128a antibody can re-
store SNAP25 expression [34]. In another study, Tat was
reported to suppress the expression of the CYP2E1 pro-
tein in neurons, through the miR-1 mediated regulatory
pathway. miR 1 was found to target the Mef2A gene;
which in turn induced an miRNA cluster (miR-379 to
410) in neurons, which is important for dendritogenesis
[37].
Other viral proteins have also been reported to sup-
press the cellular TRAF3 expression level [26]. Virus
infection or exposure to double-stranded RNA has also
been documented to decrease TRAF3 levels in a dose-
dependent manner [38]. Both the mRNA and protein
Figure 7 Phosphorylated state and total interferon regulatory factor (IRF)3 and IRF7 changes in CHME3 cells treated with TatC and
transfected with miR-32. (a) Western blot analysis for phosphorylated (p)-IRF7 and total IRF7 in CHME3 cells after Tat C treatment and miR-32
transfection. Expression levels of both p-IRF7 and total IRF7 expression levels increased with both treatments. (b) Western blot analysis for p-IRF3
and total IRF3 in Tat C-treated and miR-32-transfected samples of CHME3 cells. Both total IRF3 and pIRF3 were upregulated with both treatments.
Tat C at 500 ng/ml was applied for 24 hours. After 24 hours of miR-32 transfection, cells were harvested and lysed for protein samples and RNA
isolation. (c,d) Densitometry analysis of p-IRF3, total IRF3, p-IRF7, and total IRF7 normalized to β-tubulin. All experiments were repeated three
times, and data are presented as mean± SE (error bars). Results were significant (*P≤ 0.05).
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levels of the TRAF3 adaptor molecule have been
reported to be downregulated in herpes simplex virus
(HSV) infection [26]. Therefore, we designed this study
to understand the mechanism by which extracellularly
secreted HIV protein can affect gene expression in un-
infected cells.
Bioinformatic databases predicted that a conserved rec-
ognition sequence for miR-32 was present in the 3′ UTR
of TRAF3 (Figure 6A). miR-32 can regulate TRAF3 at the
post-transcriptional level, through direct targeting of the
TRAF3 3′ UTR. Target validation was performed using a
reporter construct, having a firefly luciferase coding region
fused with the 3′ UTR of TRAF3. By using a luciferase re-
porter assay, we showed that TRAF3 is indeed a direct
target for miR-32. The targeting of miR-32 for the 3′ UTR
of TRAF3 was specific as shown by the parallel experi-
ment, in which irrelevant miR-146 was not able to affect
the luciferase level.
The complementary sequence in the TRAF3 3′ UTR
was modified by deleting four bases (TATT) at positions
463 to 466 to remove the binding site for miR-32. Luci-
ferase expression was unaffected by using a mutated
TRAF3 3′ UTR construct co-transfected with miR-32.
This observation clearly supports the specificity of miR-
32 binding to the TRAF3 3′ UTR in microglial cells.
The complementary interaction between miR-32 and
TRAF3 mRNA results in translational inhibition, leading
to reduced expression of TRAF3 protein in CHME3 cells
exposed to HIV-1 Tat C protein.
When miR-32 was overexpressed, the levels of TRAF3
mRNA and protein were downregulated in CHME3 cells
(Figure 4). This effect can be simply attributed to enhanced
cellular level of miR-32. The increase in miR-32 expres-
sion was confirmed by qPCR of miR-32, compared with
CHME3 cells transfected with the empty vector
(Figure 4b). The presence of complementary binding
sites in the 3′ UTR of TRAF3 mRNA for miR-32 is most
likely the way in which overexpression of miR-32
resulted in reduced expression of TRAF3.
To verify the specificity of miR-32 targeting to TRAF3
mRNA and blockage of translation, the level of cellular
miR-32 was blocked by transfecting cells with anti-miR-32.
This rescued the expression of TRAF3 protein and resulted
in an enhanced level of TRAF 3, compared with control
Figure 8 Recovery of tumor necrosis factor receptor-associated factor 3 (TRAF3) expression by anti-miR-32 transfection suppresses
expression levels of total interferon regulatory factor (IRF)3 and IRF7. (a) CHME3 cells were transfected with Cy3-labeled control anti-miR,
anti-miR-32 and anti-miR-32 plus Tat C treatment. Phosphorylated (p)IRF3 level increased after anti-miR-32 treatment, while the total IRF3 level
was downregulated in anti-miR-32-transfected cells, showing a positive relationship between cellular TRAF3 level and activation of IRF3. (b) pIRF7
was increased after anti-miR-32 treatment and anti-miR-32 plus Tat C treatment, again showing a positive role of TRAF3 in IRF7 activation. Total
IRF7 level was decreased in anti-miR-32-transfected cells showing that recovery of TRAF3 could modulate the transcription of IRF3and IRF7. (c,d)
Densitometry analysis of pIRF3, pIRF7, total IRF3 and total IRF7 normalized to β-tubulin. Experiments were performed three times and data are
presented as mean± SE. Results were significant (*P≤ 0.05).
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cells (Figure 5). This observation particularly revealed the
inhibitory function of miR-32 on the expression of TRAF3.
Blockage of cellular miR-32 by application of anti-miR-32
would have occupied the binding sites of mature miR-32,
leaving the 3′ UTR of TRAF3 unrestricted, which resulted
in enhanced protein expression. Additionally, when anti-
miR-32-transfected cells were incubated with Tat C, the
TRAF3 protein level was maintained at a higher level
(Figure 5c). This suggests that anti-miR-32 could nullify
the effect of Tat C-mediated upregulation of miR-32, and
subsequent suppression of TRAF3 expression.
Modulation in TRAF3 expression could affect the im-
mune functions of microglial cells. To study the down-
stream effect of TRAF3 reduction in altering the immune
response, we studied the cellular expression levels of IRF3
and IRF7. IRFs are a family of transcription factors that
play important roles in host defense systems [39]. In Tat
C-treated and miR-32 transfected CHME3 cells, levels of
phosphorylated IRF3 and IRF7 were higher. These results
are in agreement with earlier reported functions of TRAF3
as a potent suppressor of inflammatory responses during
overactivation in cells caused by any pathogenic insult
[28]. In the present study, we found that the expression of
TRAF3 decreased along with the increase in phosphory-
lated forms of IRF3 and IRF7 and levels of total IRF3 and
total IRF7 after Tat C treatment or miR-32 overexpression.
These findings show that changes in TRAF3 level affect
expression levels of both pIRF3 and pIRF7, which can dir-
ectly trigger the immune response, as well as the expres-
sion of total IRF3/7.
In another gain-of-function study of TRAF3, anti-miR-32
was transfected into CHME3 cells to assess the expression
levels of phosphorylated forms of IRF3/7 and total IRF3/7.
The phosphorylated IRF3/7 levels were found to be signifi-
cantly higher, than those of the control (Figure 8), but total
IRF3 and total IRF7 protein levels were decreased in anti-
miR-32 transfected cells (Figure 8). These results are in ac-
cordance with the previously reported dual-mode repressor
function of TRAF3, as adequate TRAF3 expression is
required for the immune response [25] and for derepres-
sion of the alternative NF-κB pathway [27]. When TRAF3
protein levels are reduced in HIV-1 Tat C treated and miR-
Figure 9 Modulation of tumor necrosis factor receptor-associated factor 3 (TRAF3) protein level alters the interferon regulatory factor
(IRF)3 and IRF7 mRNA level. (a,b) CHME3 cells were treated with Tat C protein for 24 hours and transfected with miR-32, respectively. Relative
fold changes in mRNA levels were determined for IRF3 and IRF7 using quantitative(q)PCR with SYBR green. As a consequence of Tat C treatment
and miR-32 overexpression, the transcript expression levels of IRF3 and IRF7 increased. (c) After inhibiting the cellular miR-32 via application of
anti-miR, the transcript level of both IRF3 and IRF7 was reduced. In cells treated with anti-miR-32 plus Tat C, the transcript levels of IRF3 and IRF7
were lower than those in control CHME3 cells. All experiments were repeated three times, and data are presented as mean± SE. Relative change
in IRF3 transcript in miR-32 transfected cells compared with empty vector were significant ***P≤ 0.0005, **P≤ 0.005 and *P ≤0.05 in respective
graphs.
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32-transfected cells, the repressive function of TRAF3 is
removed, leading to activation of the non-canonical NF-κB
pathway. As documented in previous studies, TRAF3 has
been shown to bind constitutively to NIK (an essential acti-
vator of the alternative NFκB pathway) in unstimulated
cells, and to block the activation of the non-canonical NF-
κB pathway [40,41]. Our data suggest that reduction in
TRAF3 level could release the NIK, which might lead to
activation of the non-canonical NF-κB pathway. Constitu-
tive activation of the NF-κB2 pathway has been reported as
a consistent attribute of TRAF3 deficiency in multiple cell
types [42]. However, TRAF3-deficient cells display only a
partial reduction in IFN production after RNA virus infec-
tion and NF-κB activation [43].
Virus-triggered ubiquitylation of TRAF3 and TRAF6 by
cIAP1 and cIAP2 has been reported as a necessary step for
type I IFN induction and cellular antiviral response [29].
Degradative ubiquitination of TRAF3 has been reported to
be necessary for the activation of mitogen-activated protein
kinases and production of inflammatory cytokines [44].
A small interfering RNA-mediated depletion study of
TRAF3 in DLD1 cells also showed a suppressive func-
tion of TRAF3 [27]. Decreased TRAF3 association with
LTBR enhanced the recruitment of TRAF2 and IKK1 to
LTBR-induced signaling complexes [27]. A reduced level
of TRAF3 causes specific accumulation of a particular
subset of NF-κB regulators, including key components
of NF-κB2, such as p100, RelB, and NIK [27]. Another
study showed that excess TRAF3 prevents recruitment
of components (TRAF2 and IKK1) to receptor com-
plexes necessary for NF-κB1 activation [45].
The changes in TRAF3 protein affected the total protein
level of both IRF3 and IRF7 (Figure 5, Figure 7, Figure 8).
Tat C-mediated miR-32 overexpression induced the expres-
sion levels of IRF3 and IRF7, indicating the correlation of
reduced TRAF3 with increase in IRF3/7. Further, recovery
of TRAF3 via anti-miR32 transfection resulted in decreased
IRF3/7 at both at the mRNA and (Figure 9) and protein
levels (Figure 8). Induction of type I IFNs requires coordi-
nated and cooperative activation of the transcription factors
IRF3/7 and NF-κB [46]. IFN-β is the early-phase IFN,
which is primarily regulated by IRF3, whereas IFN-α is the
late-phase IFN, activated by IRF7 through the STAT1 path-
way [47]. Thus, HIV-1 Tat C protein can modulate the
innate immune response by affecting the expression level
of IRF3/7 operating via the TRAF3 expression level under
the control of miR-32. In the present study,we suggest a
new model (Figure 10) of miRNA-mediated regulation of
Figure 10 Proposed model for HIV-1 Tat C-induced, miR-32-mediated post-transcriptional regulation of tumor necrosis factor
receptor-associated factor 3 (TRAF3). In response to HIV-1 Tat C exposure of human microglial cells, miR-32 was upregulated, consequently
downregulating the protein level of TRAF3 post-transcriptionally by binding to its 3′ untranslated region. The miRNA inhibitor against miR-32,
ant-miR-32, reduced the cellular level of miR-32 and rescued the expression level of TRAF3 protein. The cellular expression level of TRAF3 protein
had an inverse relationship to the expression level of interferon regulatory factor (IRF)3/7 and this could perturb the expression of inflammatory
genes in microglial cells after exposure to HIV-1 Tat C protein.
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the TRAF3 adaptor molecule in response to HIV-1 Tat C
protein in microglial cells. Such miRNA-mediated dysregu-
lation in TRAF3 expression might affect the immune acti-
vation of microglial cells, and thus might be one of several
factors affecting neuroinflammation in patients infected
with HIV. Further studies are required to understand the
molecular basis of this regulation.
Conclusion
In this study, we found that the expression of cellular
TRAF3 protein in human microglial cells exposed to
HIV-1 Tat C protein was regulated by cellular miR-32.
The changes in expression levels of TRAF3 mediated by
miR-32 resulted in changes in the expression pattern of
cellular IRF3 and IRF7, which might lead to changes in
interferon stimulatory genes. A well-orchestrated regula-
tion of the innate immune response is very important to
prevent damage caused by excessive or dysregulated ac-
tivation of immune signaling factors. This study demon-
strates the plausible mechanism of Tat-induced miRNA
mediated dysregulation of the immune adaptor molecule
TRAF3 in human microglial cells.
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